HYDERABAD, India and PRINCETON, N.J. — Dr. Reddy’s Laboratories announced today that it has received final approval from the U.S. Food and Drug Administration (USFDA) and is launching buprenorphine and naloxone sublingual film, 2 mg/0.5 mg, 4 mg/1 mg, 8 mg/2 mg, and 12 mg/3 mg, a therapeutic equivalent generic version of Suboxone (buprenorphine and
PRINCETON, N.J. — Dr. Reddy’s Laboratories has launched levocetirizine dihydrochloride tablets 5 mg, an over-the-counter allergy medication, in the U.S. market. Dr. Reddy’s said its levocetirizine dihydrochloride tablets are a generic version of Xyzal Allergy 24HR Tablets from Chattem-Sanofi. The 5-mg Dr. Reddy’s product comes in various consumer-oriented package sizes. “This first-to-market launch for the
HYDERABAD, India — Dr. Reddy’s Laboratories Ltd. has launched bupropion HCl extended-release tablets, an antidepressant medication. Dr. Reddy’s said its product, a generic version of Wellbutrin SR sustained-release tablets from GlaxoSmithKline, comes in strengths of 100 mg, 150 mg and 200 mg in 60-, 100- and 500-count bottles. An antidepressant of the aminoketone drug class,
PRINCETON, N.J. — Promius Pharma LLC, a subsidiary of Dr. Reddy’s Laboratories, has unveiled its new visual identity and corporate brand: The Power of Humans Being. The initiative is designed to express the core belief at Promius Pharma that “every patient is a person first” and its mission to “help patients get back to what
HYDERABAD, India — Dr. Reddy’s Laboratories Ltd. has acquired six over-the-counter health product brands from Ducere Pharma LLC. Financial terms of the agreement weren’t disclosed. India-based Dr. Reddy’s, which has its U.S. office in Princeton, N.J., said the deal brings the company into the consumer health care arena. The brands being acquired from New Hope,
WILMINGTON, Mass. — CutisPharma has entered into active pharmaceutical ingredient (API) supply and joint development pacts with Dr. Reddy’s Laboratories Ltd. CutisPharma, which focuses on products for the prescription compounding market, said Tuesday that it aims to advance several programs in its research and development portfolio — including RM-02, RM-03 and RM-06 — toward Food
PRINCETON, N.J. — Promius Pharma LLC has received Food and Drug Administration approval for Sernivo Spray 0.05%, a psoriasis medication. A prescription topical steroid, Sernivo Spray (betamethasone dipropionate 0.05%) is indicated for the treatment of mild to moderate plaque psoriasis in adult patients, according to Promius, the U.S. subsidiary of India-based Dr. Reddy’s Laboratories. “The
PRINCETON, N.J. — Dr. Reddy’s Laboratories has launched a new logo and new brand initiative under the theme Good Health Can’t Wait. The new logo is described as an expression of empathy and dynamism, which helps keep patients at the center of everything that Dr. Reddy’s does. “Empathy helps gain insights into patients’ needs, and